Mylan NV (MYL)

17.24
0.03 0.17
NASDAQ : Health Technology
Prev Close 17.27
Open 17.13
Day Low/High 17.06 / 17.53
52 Wk Low/High 16.63 / 35.07
Volume 6.99M
Avg Volume 5.88M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 8.89B
EPS 0.70
P/E Ratio 196.67
Div & Yield N.A. (N.A)

Latest News

The Week Ahead: Earnings Season Is Far From Over

The Week Ahead: Earnings Season Is Far From Over

Disney, Qualcomm and Square are among 75 key reports we are watching.

Jim Cramer: Here's Why the Market's So Feckless and Reactive

Jim Cramer: Here's Why the Market's So Feckless and Reactive

So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Financial Details for Pfizer on Mylan

More Generic Mergers Ahead?

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

Mylan Downgraded to Neutral at Mizuho

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon

Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon

The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.

How to Play Trump's New 'War' With Iran: Market Recon

How to Play Trump's New 'War' With Iran: Market Recon

While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.

Subscriber Comment of the Day (Part Deux)

Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Generic-Drug Stocks Are Looking Sickly

I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.

Staying Liquid

I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...